Tuesday after hours
The following small-cap companies were making news in after-hours trading Tuesday:
MSC Software Corp. (Nasdaq: MSCS) was off by $0.67, or nearly 5%, to $12.85 on heavy volume in after-hours trading Tuesday after the company announced preliminary revenue results that came in below analysts’ expectations. The Santa Ana, Calif.-based software and services provider said it expects to report revenue in the range of $56 million to $58 million for the first quarter ended March 31. Four analysts polled by Thomson First Call were expecting revenue of $64.2 million. The company will report the full results May 9.
Shares of Interwoven Inc (Nasdaq: IWOV) were down $0.24, or 1.5%, to $15.90 on heavy volume after the market closed on Tuesday after it released only partial first-quarter results. The Sunnyvale, Calif.-based content management solutions provider reported first-quarter revenue of $52.7 million – in line with analysts’ expectations. However, the company did not provide earnings information or other consolidated financial returns because it is in the process of voluntarily reviewing its historical stock option grant processes. Interwoven did say that it signed on 74 new customers, including the California Department of Transportation, and AB Volvo, for the quarter ended March 31. Five analysts had estimated earnings per share of $0.12 on revenue of $52.5 million.
Shares of Stanley Furniture Company Inc. (Nasdaq: STLY) rose by $0.41, or nearly 2%, to $21.05 in after-hours trading on Tuesday after the company reported earnings per share of $0.15 on revenue of $75.1 million for the first quarter. Analysts polled by Thomson First Call had estimated earnings per share of $0.15 on revenue of $71.6 million. Looking ahead, the Stanleyville, Va., wood furniture manufacturer predicted its earnings per share for the second quarter would be in the range of $0.19 to $0.23 on revenue of $69 million to $73 million. Analysts were expecting EPS of $0.24 on revenue of $71.6 million.
Shares of Introgen Therapeutics Inc. (Nasdaq: INGN) soared $0.74, or 14.3%, to $5.90 on unusually heavy volume late Tuesday after the biopharmaceutical firm reported positive data on its Advexin treatment. In Phase II clinical trials, Austin-based Introgen found increased survival and tumor responses in 28 recurrent head and neck cancer patients following Advexin treatment.
Shares of Avistar Communications Corp. (Nasdaq: AVSR) climbed $0.13, or 8.7%, to $1.63 in after-hours trading Tuesday after the firm announced that one of its subsidiaries had been awarded two additional U.S. patents covering elements of real-time communications. The patents represent San Mateo, Calif.-based Avistar’s 75th and 76th overall in its 14-year history. Avistar develops, markets and supports a video over-IP collaboration platform.
Lexicon Genetics Inc. (Nasdaq: LEXG) said late Tuesday that it has made progress in identifying proteins involved in blood vessel organization and formation, also known as angiogenesis. The Woodlands, Tx.-based biopharmaceutical company saw shares nudge up by $0.01, or 0.28%, to $3.62 on the news. The company aims to identify promising potential drug targets for ocular diseases. Specifically, Lexicon said it plans to use the research
toward the development of novel therapeutics for the treatment of age-related macular degeneration, diabetic retinopathy, and other diseases, including cancer, in which angiogenesis plays a role.
